EUVIMEDEUVIMED entdecken
Fallbericht

Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache

Djordje Marina, Pia Burman, Marianne Klose, Olivera Casar-Borota, Raúl M Luque, Justo P Castaño, Ulla Feldt-Rasmussen

Growth Hormone & IGF Research · 2015-10 · 25 (5) · 262-267

DOI: 10.1016/j.ghir.2015.07.003 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Growth Hormone & IGF Research, 2015-10. Verfasst von Djordje Marina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Arvid Nilsson's fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Somatotropinomas have unique "fingerprints" of somatostatin receptor (sst) expression, which are targets in treatment of acromegaly with somatostatin analogues (SSAs). However, a significant expression of sst is not always related to the biochemical response to SSAs. Headache is a common complaint in acromegaly and considered a clinical marker of disease activity. SSAs are reported to have an own analgesic effect, but the sst involved are unknown. PATIENTS AND METHODS: We investigated sst expression in two acromegalic patients with severe headache and no biochemical effects of octreotide, but a good response to pasireotide. We searched the literature for determinants of biochemical and analgesic effects of SSAs in somatotropinomas. RESULTS: Case 1 had no biochemical or analgesic effects of octreotide, a semi-selective SSA, but a rapid and significant effect of pasireotide, a pan-SSA. Case 2 demonstrated discordance between analgesic and biochemical effects of octreotide, in that headache disappeared, but without biochemical improvement. In contrast, pasireotide normalized insulin-like growth factor 1. Both adenomas were sparsely granulated and had strong membranous expressions of sst2a in 50-75% and sst5 in 75-100% of tumor cells. The truncated sst5 variant TMD4 (sst5TMD4) showed expression in 20-57% of tumor cells. CONCLUSIONS: A poor biochemical response to octreotide may be associated with tumor expression of a truncated sst5 variant, despite abundant sst2a expression, suggesting an influence from variant sst5 on common sst signaling pathways. Furthermore, unrelated analgesic and biochemical effects of SSAs supported a complex pathogenesis of acromegaly-associated headache. Finally, assessment of truncated sst5 in addition to full length sst could be important for a choice of postoperative SSA treatment in somatotropinomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyAdultFemaleGrowth Hormone-Secreting Pituitary AdenomaHeadacheHuman Growth HormoneHumansOctreotidePituitary NeoplasmsReceptors, SomatostatinSomatostatinYoung Adult

Stichwörter der Autor:innen

AcromegalyAnalgesic effectHeadachePasireotideSomatostatin receptorsTruncated sst5

Substanzen

Receptors, Somatostatinsomatostatin receptor sst2AHuman Growth HormoneSomatostatinsomatostatin receptor 5pasireotidepegvisomantOctreotide

Autor:innen und Institutionen

  • Department of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Endocrinology, Skånes University Hospital, Malmö, Sweden.
  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Department of Cell Biology, Physiology and Immunology, University of Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, 14014 Córdoba, Spain; CIBER Fisiopat…
  • Department of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: ufeldt@rh.dk.

Förderung

  • Arvid Nilsson's fund

Zitieren

APA

Marina, D., Burman, P., Klose, M., Casar-Borota, O., Luque, R. M., Castaño, J. P., & Feldt-Rasmussen, U. (2015). Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache. Growth Hormone & IGF Research, 25(5), 262-267. https://doi.org/10.1016/j.ghir.2015.07.003

Vancouver

Marina D, Burman P, Klose M, Casar-Borota O, Luque RM, Castaño JP, et al. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache. Growth Hormone & IGF Research. 2015;25(5):262-267. doi:10.1016/j.ghir.2015.07.003

BibTeX
@article{Marina2015,
  author = {Marina, Djordje and Burman, Pia and Klose, Marianne and Casar-Borota, Olivera and Luque, Raúl M and Castaño, Justo P and Feldt-Rasmussen, Ulla},
  title = {Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache},
  journal = {Growth Hormone & IGF Research},
  year = {2015},
  volume = {25},
  number = {5},
  pages = {262--267},
  doi = {10.1016/j.ghir.2015.07.003}
}
Kostenlos starten →